Clinical Trials Browser

Esophageal Squamous Cell Carcinoma, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03562637 2025-05-09

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Phase 3 Active not recruiting

575 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03168880 2025-04-09

TNBC

Phase 3 Active not recruiting

720 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04296175 2025-03-26

CITRINE

Phase 3 Active not recruiting

808 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03671044 2025-03-21

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Phase 3 Recruiting

657 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

TroFuse-011

POLARIS

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

EL1SSAR

CAPItello-290

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

SASCIA

ADAPT-TN-III

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

IMpassion132

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

ADAPT-TN-IV

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

OPT-PEMBRO

ZEST

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

TORCHLIGHT

ISIdE

MOIO

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

TNBC

CITRINE

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients